(HKEX: 02162)�("Keymed" or the "Company") today announced that the prestigious medical journal Nature Medicine has published the results from the Phase III trial of its independently developed�IL-4Ra ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback